Eledon Pharmaceuticals (ELDN) filed a registration statement late Friday for the potential sale of up to $500 million of securities from time to time.
The filing covers common and preferred stock, debt securities, warrants and units.
Net proceeds will be used for general corporate purposes, the company said.